Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Atmar

Showing results (221-230 of 237) with videos related to

Pageof 24
Sort By:
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary ReportRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
The New England Journal of Medicine|January 26, 2022
Homologous and Heterologous Covid-19 Booster VaccinationsRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
Cell Reports. Medicine|July 7, 2022
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
NPJ Vaccines|July 11, 2023
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Open Forum Infectious Diseases|June 29, 2023
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test CaseAna M Ortega-Villa, Noreen A Hynes, Corri B Levine, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 24

Showing results (221-230 of 237) with videos related to

Sort By:
Pageof 24
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary ReportRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
The New England Journal of Medicine|January 26, 2022
Homologous and Heterologous Covid-19 Booster VaccinationsRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
Cell Reports. Medicine|July 7, 2022
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
NPJ Vaccines|July 11, 2023
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Open Forum Infectious Diseases|June 29, 2023
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test CaseAna M Ortega-Villa, Noreen A Hynes, Corri B Levine, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Pageof 24